TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9089559
Drug: Estradiol-releasing vaginal
Normalized name: estradiol Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol-releasing vaginal ring with a 100 mg vaginal progesterone suppository (7 days every month)
Study: 9089559
Drug: Transdermal daily
Normalized name: PATCH, TRANSDERMAL DAILY, SEQUENTIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal daily dose of 50 micrograms of estradiol with a levonorgestrel-releasing intrauterine device
Study: 3131040
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 100 mg recombinant tissue-type plasminogen activator (rt-PA) over 3 hours
Study: 31277796
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept 2 mg every 4 weeks
Study: 28007457
Drug: Vascular-targeted photodynamic
Normalized name: endothelial growth factor A, vascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vascular-targeted photodynamic therapy (4 mg/kg padeliporfin intravenously over 10 min, laser activation for 22 min 15 s)
Study: 28007457
Drug: Vascular-targeted photodynamic
Normalized name: endothelial growth factor A, vascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vascular-targeted photodynamic therapy
Study: 2857901
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus of 100 micrograms human alpha‐ANP
Study: 21544074
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen 1,000 mg
Study: 17288697
Drug: Inhaled insulin
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled insulin (HIIP; AIR inhaled insulin)
Study: 17288697
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin (regular human insulin or insulin lispro)
Study: 15337620
Drug: Standard aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard aspirin and dipyridamole treatment b.i.d. for 2 weeks
Study: 15337620
Drug: Titration with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titration with aspirin only in the morning and aspirin and dipyridamole in the evening for 5 days, followed by 9 days of standard aspirin and dipyridamole treatment
Study: 19419595
Drug: Haloperidol (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (5-20 mg/d)
Study: 1894296
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg intravenous oxyfedrine
Study: 10500058
Drug: Rofecoxib (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (25 mg once daily)
Study: 30198872
Drug: Naproxen (220
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (220 mg twice-daily)
Study: 22260859
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of fish oil (1.1 g marine n‐3 PUFA)
Study: 22260859
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of olive oil (control)
Study: 12038948
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of cevimeline 3 times daily
Study: 11920411
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of cevimeline 3 times daily
Study: 9823079
Drug: Oscillating/rotating power
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oscillating/rotating power toothbrush (Braun Oral‐B Ultra Plaque Remover‐D9)
Study: 7967427
Drug: 12 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 Gy fractionated total body irradiation (FTBI) and 2 (or 3) cytotoxic drugs (group A, n = 19)
Study: 7967427
Drug: 3 cytotoxic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 cytotoxic drugs (group B, n = 9)
Study: 15204150
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids (TCS)
Study: 25070546
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel (wPxl; 80 mg/m(2)/week ×6 with 2‐week break) plus saracatinib (S; 175 mg o.d.)
Study: 25070546
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel (wPxl; 80 mg/m(2)/week ×6 with 2‐week break) plus placebo (P)
Study: 23347605
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate 100mg daily for 5 days
Study: 23347605
Drug: Cimicifuga racimosa
Normalized name: Cimicifuga racemosa extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimicifuga racimosa 20mg daily for 10 days
Study: 17440520
Drug: Probiotic yoghurt
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic yoghurt supplement containing L. acidophilus 74-2 and B. lactis 420 (300 g/day)
Study: 17242812
Drug: Dopaminergic agents,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopaminergic agents, anticonvulsants, opioids, benzodiazepines, zolpidem, entacapone, ketamine
Study: 17242812
Drug: Gabapentin and
Normalized name: Gabapentin and mecobalamin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin and L-dopa (sustained release formulation)
Study: 12527491
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream vs Placebo
Study: 10212103
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (500 microg twice daily) for four weeks
Study: 8729126
Drug: steroids and
Normalized name: Corticosteroids and mydriatics in combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: steroids and other immunosuppressive agents (e.g., cyclosporin A)
Study: 25066554
Drug: Non-vitamin K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-vitamin K oral anticoagulants (NOACs)
Study: 27346176
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose edoxaban
Study: 27346176
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose edoxaban
Study: 24618935
Drug: Empiric antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric antibiotic therapy in FN episodes with bacteremia
Study: 20549832
Drug: everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: everolimus 10 mg/d
Study: 12410482
Drug: Switching from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching from protease inhibitors to alternative drugs
Study: 12410482
Drug: Switching thymidine
Normalized name: Thymidine
DrugBank: Thymidine (DB04485)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching thymidine analogue reverse-transcriptase inhibitors
Study: 12410482
Drug: Substitution of
Normalized name: hydroxypropyl cellulose, low substituted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substitution of other agents for protease inhibitors
Study: 10190874
Drug: Testosterone (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (2.5 mg IV in 5 minutes)
Study: 30168611
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) mediated by methylene blue and red laser diode (Periowave®, λ = 670 nm, 200 mW)
Study: 21115098
Drug: Sandblasting with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandblasting with aluminium oxide particles followed by silane coupling agent
Study: 21115098
Drug: Immersion in
Normalized name: OCTOCRYLENE 10 g in 100 g / HOMOSALATE 10 g in 100 g / AVOBENZONE 3 g in 100 g / OCTISALATE 4.5 g in 100 g TOPICAL LOTION [Eucerin Face immersive Hydration]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immersion in 9.6% hydrofluoric acid gel for 60 s and silanization for 60 s
Study: 21115098
Drug: No surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: No surface treatment (Control)
Study: 18046883
Drug: Alpha-1-blockers (A1Bs)
Normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-1-blockers (A1Bs)
Study: 18046883
Drug: Alpha-2 agonists
Normalized name: (2S)-alpha-2-Amino-4-methylvaleric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-2 agonists (A2Ags)
Study: 11601508
Drug: Intravenous 10%
Normalized name: fat emulsion, intravenous 10% intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 10% dextran 40
Study: 9240678
Drug: Wallstent with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wallstent with periprocedural heparin
Study: 9240678
Drug: Wallstent without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Wallstent without periprocedural heparin
Study: 9240678
Drug: Palmaz stent
Normalized name: castor fiber scent gland secretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palmaz stent with periprocedural heparin
Study: 9240678
Drug: Palmaz stent
Normalized name: castor fiber scent gland secretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palmaz stent without periprocedural heparin
Study: 2955033
Drug: 30 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 micrograms ethinyl oestradiol daily (OC)
Study: 27474356
Drug: Prasugrel (2-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (2-30 mg single administration)
Study: 27474356
Drug: Prasugrel (2.5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (2.5-10 mg multiple administration)
Study: 27474356
Drug: Prasugrel (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (up to 30 mg single administration and up to 10 mg maintenance dose)
Study: 24456422
Drug: L-PGDS
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-PGDS
Study: 16310197
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (300 ml for 15 days)
Study: 16310197
Drug: White wine
Normalized name: White wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: White wine (300 ml for 15 days)
Study: 10762178
Drug: Methylprednisolone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (30 mg x kg(‐1) over 1 h, followed by 5.4 mg x kg(‐1) x h(‐1) for 23 h)
Study: 10762178
Drug: Nimodipine (0.015
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (0.015 mg x kg(‐1) x h(‐1) for 2 h followed by 0.03 mg x kg(‐1)h(‐1) for 7 days)
Study: 10762178
Drug: No medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medical treatment (Control group)
Study: 1483668
Drug: Neomycin sulfate
Normalized name: Neomycin Sulfate
DrugBank: Neomycin (DB00994)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neomycin sulfate (6 g per os)
Study: 29126314
Drug: Standard single-agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard single-agent therapy
Study: 27154847
Drug: Filgrastim-stimulated marrow
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Filgrastim-stimulated marrow (G-BM)
Study: 27154847
Drug: Filgrastim-mobilized peripheral
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Filgrastim-mobilized peripheral blood (G-PB)
Study: 21056464
Drug: Rivastigmine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine (1.5 mg twice daily increasing to 6 mg twice daily) as an adjunct to usual care with haloperidol
Study: 21056464
Drug: Placebo as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo as an adjunct to usual care with haloperidol
Study: 17785930
Drug: Efonidipine 20‐60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efonidipine 20‐60 mg twice daily
Study: 17785930
Drug: Amlodipine 2.5‐7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 2.5‐7.5 mg once daily
Study: 7526676
Drug: Celiprolol (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol (selective beta blocker) for 8 weeks
Study: 19466504
Drug: Ciprofloxacin (CIP)
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin (CIP) at 300 mg twice daily by intravenous drip infusion
Study: 19466504
Drug: Imipenem/cilastatin (IPM/CS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin (IPM/CS) at 500 mg twice daily by intravenous drip infusion
Study: 343993
Drug: 0.1% halcinonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% halcinonide applied once daily
Study: 343993
Drug: 0.05% betamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% betamethasone dipropionate cream applied twice daily
Study: 26538383
Drug: Not the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not the Ice Cream Van (NTICV)
Study: 19191743
Drug: TSH levels
Normalized name: TSH-releasing hormone
DrugBank: Protirelin (DB09421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TSH levels (0.3-10.0 mIU/L)
Study: 28437263
Drug: CHO group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO group received oral CHO (400 ml) the prior evening and 2 to 3 hours before surgery.
Study: 25675222
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid gel injection
Study: 25675222
Drug: Sterile water
Normalized name: sterile water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile water injection
Study: 16828500
Drug: 0.3-mg pegaptanib
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3-mg pegaptanib continued for 48 weeks (8 injections)
Study: 16828500
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care or discontinuation of pegaptanib
Study: 9603290
Drug: 0.25% nipradilol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% nipradilol (N = 9) twice daily for 15 days
Study: 9603290
Drug: 0.01% bunazosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01% bunazosin (N = 10) twice daily for 20 days
Study: 8256008
Drug: Transdermal nitroglycerine
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerine (TNG) - 2 cm of NTG gel administered once a day
Study: 3899248
Drug: Single phenol
Normalized name: Phenol
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single phenol injection
Study: 3899248
Drug: Multiple phenol
Normalized name: Phenol
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple phenol injection
Study: 31888708
Drug: Cognitive behavioral-physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral-physical therapy (CBPT) intervention
Study: 29384722
Drug: ADT in
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADT in combination with docetaxel 75 mg/m2 for up to six cycles
Study: 29384722
Drug: Chemohormonal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemohormonal therapy for high-volume disease (n = 513)
Study: 29384722
Drug: Chemohormonal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemohormonal therapy for low-volume disease (n = 277)
Study: 27105868
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg resveratrol
Study: 18785409
Drug: rhGM‐CSF hydrogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGM‐CSF hydrogel (100 microg/10 g/100 cm2/d)
Study: 9625104
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (1200 mg elemental Ca/d)
Study: 31418151
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet + 1 g/kg of organic mineral mixture
Study: 31418151
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet + 0.5 g/kg of organic mineral mixture
Study: 31418151
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet + organic mineral mixture (0.5 g/kg and 1 g/kg)
Study: 25867075
Drug: No written
Approvals — FDA: no, EMA: no, PMDA: no
Description: No written instructions other than prescriptions
Study: 21148516
Drug: Cranberry juice
Normalized name: cranberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry juice (8 oz of 27% cranberry juice twice daily)
Study: 19351303
Drug: Chemotherapy Symptom
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy Symptom Assessment Scale
Study: 14643116
Drug: Ximelagatran (fixed-dose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran (fixed-dose, 36 mg twice daily)
Study: 14643116
Drug: Warfarin (adjusted-dose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (adjusted-dose, INR 2.0-3.0)
Study: 25040321
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg of sumatriptan subcutaneously
Study: 9484515
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of dihydroergotamine intramuscularly
Study: 7524381
Drug: Prostaglandin- and
Normalized name: Prostaglandin analogues, antiglaucoma drugs and miotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin- and kininogenesis inhibitors (acelysin and kontrykal)
Study: 1326348
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg rifabutin
Study: 1326348
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg rifabutin
Study: 1326348
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg rifabutin
Study: 1326348
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg rifabutin
Study: 1326348
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg rifampicin
Study: 1326348
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg rifampicin
Study: 3885634
Drug: Postoperative radio-
Normalized name: Valerianae radix
DrugBank: Valerian (DB13196)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative radio- and chemotherapy (group A)
Study: 3885634
Drug: Combined longterm
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined longterm chemotherapy (group B)
Study: 16705846
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not specified what the control treatment was)
Study: 31671938
Drug: Radiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy with concurrent temozolomide (75 mg/m2/day) followed by adjuvant temozolomide (150-200 mg/m2/day for 5 days during six 28-day cycles)
Study: 31215838
Drug: SFTSV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFTSV vaccine
Study: 21859323
Drug: Non-surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical periodontal treatment (baseline) and subgingival debridement (3-month follow-up)
Study: 21859323
Drug: Non-surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical periodontal treatment and supragingival prophylaxis (3-month follow-up)
Study: 19208404
Drug: Modafinil (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (up to 300 mg/day for 4 weeks)
Study: 17389710
Drug: Exercise (EX),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise (EX), 20% increase in energy expenditure through daily exercise (n = 18)
Study: 16229115
Drug: New letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: New letrozole preparation
Study: 7768250
Drug: 200-300 mg
Normalized name: allopurinol 300 MG / lesinurad 200 MG [Duzallo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200-300 mg sustained release diltiazem (200-300 SR) administered once daily
Study: 7768250
Drug: Standard diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard diltiazem (D) given three or four times daily
Study: 2100165
Drug: Bupranolol 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupranolol 0.25% in an oily solution
Study: 27600367
Drug: Tofacitinib re-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib re-treatment (5 mg and 10 mg)
Study: 24880907
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group 1 (n = 66) received 125 ml of ONS twice per day, at 12 and 17 o'clock
Study: 24880907
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group 2 (n = 80) received 62 ml of ONS four times a day, at 8, 12, 17 and 20 o'clock
Study: 24880907
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care group (n = 88) offered ONS 125 ml twice per day in between meals
Study: 21069516
Drug: Melatonin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (3 mg sustained release)
Study: 21069516
Drug: Light treatment
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light treatment (0700 to 0800 hours)
Study: 21069516
Drug: Melatonin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (3 mg sustained release) plus Light treatment
Study: 17213754
Drug: ERr 731
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ERr 731 (1 enteric coated tablet daily for 12 weeks)
Study: 17213754
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 tablet daily for 12 weeks)
Study: 2502048
Drug: Peripheral Parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral Parenteral Nutrition (PPN)
Study: 900915
Drug: Cefaclor 250
Normalized name: cefaclor 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 250 mg orally
Study: 900915
Drug: Cephalexin 250
Normalized name: cephalexin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin 250 mg orally
Study: 1375713
Drug: Trabeculectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabeculectomy with collagen sponge implant containing 100 micrograms of antimetabolite (5‐fluorouracil or bleomycin)
Study: 15918297
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy with a monomeric allergoid of Cupressus arizonica pollen